High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review

Sophie L. Gerritse; Jorien B.E. Janssen; Mariette Labots; Ralph de Vries; Michelle Rudek; Michael Carducci; Nielka P. van Erp; Henk M.W. Verheul

doi:10.1016/j.ctrv.2021.102171

High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review

Sophie L. Gerritse, Jorien B.E. Janssen, Mariette Labots, Ralph de Vries, Michelle Rudek, Michael Carducci, Nielka P. van Erp, Henk M.W. Verheul

School of Medicine

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead to broader kinase inhibition, which might be essential for the optimal suppression of tumor growth and induction of apoptosis. To reach these higher intratumoral concentrations, without encountering dose limiting toxicity, alternative TKI dosing strategies employing higher daily and high intermittent doses have been studied. In this systematic review, we evaluated the current clinical evidence to support (intermittent) high TKI dosing regimens. Methods: A systematic review was conducted in the following databases: PubMed®, EMBASE® and Cochrane Library

Original language	English (US)
Article number	102171
Journal	Cancer Treatment Reviews
Volume	97
DOIs	https://doi.org/10.1016/j.ctrv.2021.102171
State	Published - Jun 2021

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2021.102171

Cite this

@article{b746f967d26f43399450cca9bad1eb37,

title = "High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review",

abstract = "Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead to broader kinase inhibition, which might be essential for the optimal suppression of tumor growth and induction of apoptosis. To reach these higher intratumoral concentrations, without encountering dose limiting toxicity, alternative TKI dosing strategies employing higher daily and high intermittent doses have been studied. In this systematic review, we evaluated the current clinical evidence to support (intermittent) high TKI dosing regimens. Methods: A systematic review was conducted in the following databases: PubMed{\textregistered}, EMBASE{\textregistered} and Cochrane Library",

author = "Gerritse, {Sophie L.} and Janssen, {Jorien B.E.} and Mariette Labots and {de Vries}, Ralph and Michelle Rudek and Michael Carducci and {van Erp}, {Nielka P.} and Verheul, {Henk M.W.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = jun,

doi = "10.1016/j.ctrv.2021.102171",

language = "English (US)",

volume = "97",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - High-dose administration of tyrosine kinase inhibitors to improve clinical benefit

T2 - A systematic review

AU - Gerritse, Sophie L.

AU - Janssen, Jorien B.E.

AU - Labots, Mariette

AU - de Vries, Ralph

AU - Rudek, Michelle

AU - Carducci, Michael

AU - van Erp, Nielka P.

AU - Verheul, Henk M.W.

PY - 2021/6

Y1 - 2021/6

N2 - Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead to broader kinase inhibition, which might be essential for the optimal suppression of tumor growth and induction of apoptosis. To reach these higher intratumoral concentrations, without encountering dose limiting toxicity, alternative TKI dosing strategies employing higher daily and high intermittent doses have been studied. In this systematic review, we evaluated the current clinical evidence to support (intermittent) high TKI dosing regimens. Methods: A systematic review was conducted in the following databases: PubMed®, EMBASE® and Cochrane Library

AB - Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead to broader kinase inhibition, which might be essential for the optimal suppression of tumor growth and induction of apoptosis. To reach these higher intratumoral concentrations, without encountering dose limiting toxicity, alternative TKI dosing strategies employing higher daily and high intermittent doses have been studied. In this systematic review, we evaluated the current clinical evidence to support (intermittent) high TKI dosing regimens. Methods: A systematic review was conducted in the following databases: PubMed®, EMBASE® and Cochrane Library

UR - http://www.scopus.com/inward/record.url?scp=85103624924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103624924&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2021.102171

DO - 10.1016/j.ctrv.2021.102171

M3 - Review article

C2 - 33823432

AN - SCOPUS:85103624924

SN - 0305-7372

VL - 97

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

M1 - 102171

ER -

High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this